Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298788 | 0.83 | CRBN (0.51) | CRBNDDB1CA1CA2CA12 | |
| SCHEMBL3631245 | 0.83 | MAPT (0.47) | CRBNDDB1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6297778 | 0.80 | GAA (0.51) | CRBNDDB1TSHRMMP2GAA | |
| SCHEMBL20879956 | 0.80 | CRBN (0.45) | CRBNDDB1CA1CA2CA12 | |
| SCHEMBL11835120 | 0.70 | MAP3K14 (0.43) | CYP19A1CRBNDDB1TDP1ALDH1A1 | |
| SCHEMBL10876701 | 0.70 | HTR6 (0.44) | CRBNDDB1HTR6TSHRLMNA | |
| SCHEMBL30158537 | 0.69 | MAP3K14 (0.41) | CYP19A1CRBNDDB1TDP1 | |
| SCHEMBL4226223 | 0.69 | MAP3K14 (0.41) | CYP19A1CRBNDDB1 | |
| SCHEMBL5086277 | 0.69 | MAP3K14 (0.41) | CYP19A1CRBNDDB1TDP1 | |
| SCHEMBL3274268 | 0.68 | CYP19A1 (1.00) | CYP19A1CRBNDDB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667046-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7423155-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080145907-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-7361767-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-04-22 | — | — | US | disclosed |
| US-7351838-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070154937-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1689709-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050227076-A1 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | disclosed |
| WO-2005049565-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050106709-A1 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145907-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | NAPA, MSN, NSFL1C | CYP19A1 3891/4885CRBN 375/4885DDB1 1758/4885 |
| US-20070154937-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | NAPA, MSN, NSFL1C | CYP19A1 3891/4885CRBN 375/4885DDB1 1758/4885 |
| US-20050106709-A1 | N-sulfonyldicarboximide containing tethering compounds | NAPA, MSN, NSFL1C | CYP19A1 3891/4885CRBN 375/4885DDB1 1758/4885 |
| US-20050227076-A1 | N-sulfonyldicarboximide containing tethering compounds | NAPA, MSN, NSFL1C | CYP19A1 3891/4885CRBN 375/4885DDB1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.